Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is evaluated if the Botulinum Toxin Type A is superior to 0,9% saline in treatment of cranial Allodynia in patients with headache.

Hypothesis

H(0): Botulinum Toxin Type A is not superior to 0,9% saline in treatment of cranial Allodynia in patients with headache

H (1): Botulinum Toxin Type A is superior to 0,9% saline in treatment of cranial Allodynia in patients with headache

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of Bahia
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA; Polystyrene sulfonic acid

Criteria

Inclusion Criteria:

• Patients diagnosed with tensional headache or migraine as The International Classification of Headache Disorders, 2nd Edition - ICHD II

• Patients from both sexes older than 18 years

Exclusion Criteria:

• Fill the diagnostics criteria for more than one type of primary headache as ICHD II

• Another neurological disease or systemic illness that causes headache.

• Condition that contraindicate the use of Study's Medication.

• Cognitive impairment

• Use of botulinum toxin within the last six months

• Blood, liver, or kidney disorders and pregnant or lactating women